Global Candesartan

Candesartan Comprehensive Study by Application (Hypertension, Cardiovascular Risks, Chronic Kidney Diseases), Doses (4 mg, 8 mg, 16 mg, 32 mg), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End User (Adult, Children and Adolescent) Players and Region - Global Market Outlook to 2028

Candesartan Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Candesartan Market Overview:
Candesartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). It works by relaxing blood vessels so blood can flow more easily. Candesartan is used to treat hypertension (high blood pressure). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This medication is also used to treat heart failure. These factors are driving the growth of the global candesartan market.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Increasing Demand at Asia-Pacific Regions

Market Growth Drivers:
High Incidence of Target Diseases Such as Highblood Pressure, and Others and Increasing Customer's Awareness of Health Consciousness

Challenges:
Various Side Effects of the Candesartan

Restraints:
Increasing Commercial Availability Hamper the Patients

Opportunities:
Technological Advancements such as Advanced Healthcare Infrastructure and Diagnosis Process and Upsurge Demand for Accurate Treatment Options

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Bayer AG (Germany), Alvogen (United States), Ahn-Gook Pharmaceutical Co., Ltd. (South Korea), GlaxoSmithKline plc (United Kingdom), Tocris Bioscience (United Kingdom), Abmole (United States), Merck KGaA (Germany), AstraZeneca (United Kingdom), ANI Pharmaceuticals (United States) and Shenzhen HEC Industrial Development Co., Ltd. (China). Additionally, following companies can also be profiled that are part of our coverage like Mylan N.V. (United States) and Cadila Healthcare (India). Analyst at AMA Research see European Players to retain maximum share of Global Candesartan market by 2028. Considering Market by Doses, the sub-segment i.e. 4 mg will boost the Candesartan market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Candesartan market. Considering Market by End User, the sub-segment i.e. Adult will boost the Candesartan market.

In August 2022, Bayer launched its drug finer enone to treat chronic kidney disease associated with type-2 diabetes in India. The drug, touted as a potential blockbuster drug for the German pharmaceutical firm

This medication is not recommended for use in children younger than 1 year by the FDA.due to the increased risk of side effects.

What Can be Explored with the Candesartan Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Candesartan Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Candesartan
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Candesartan market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Candesartan market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Candesartan Manufacturers, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Other.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • Hypertension
  • Cardiovascular Risks
  • Chronic Kidney Diseases
By Doses
  • 4 mg
  • 8 mg
  • 16 mg
  • 32 mg

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By End User
  • Adult
  • Children and Adolescent

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Incidence of Target Diseases Such as Highblood Pressure, and Others
      • 3.2.2. Increasing Customer's Awareness of Health Consciousness
    • 3.3. Market Challenges
      • 3.3.1. Various Side Effects of the Candesartan
    • 3.4. Market Trends
      • 3.4.1. Increasing Demand at Asia-Pacific Regions
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Candesartan, by Application, Doses, Distribution Channel, End User and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Candesartan (Value)
      • 5.2.1. Global Candesartan by: Application (Value)
        • 5.2.1.1. Hypertension
        • 5.2.1.2. Cardiovascular Risks
        • 5.2.1.3. Chronic Kidney Diseases
      • 5.2.2. Global Candesartan by: Doses (Value)
        • 5.2.2.1. 4 mg
        • 5.2.2.2. 8 mg
        • 5.2.2.3. 16 mg
        • 5.2.2.4. 32 mg
      • 5.2.3. Global Candesartan by: Distribution Channel (Value)
        • 5.2.3.1. Hospital Pharmacies
        • 5.2.3.2. Retail Pharmacies
        • 5.2.3.3. Online Pharmacies
      • 5.2.4. Global Candesartan by: End User (Value)
        • 5.2.4.1. Adult
        • 5.2.4.2. Children and Adolescent
      • 5.2.5. Global Candesartan Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Candesartan (Volume)
      • 5.3.1. Global Candesartan by: Application (Volume)
        • 5.3.1.1. Hypertension
        • 5.3.1.2. Cardiovascular Risks
        • 5.3.1.3. Chronic Kidney Diseases
      • 5.3.2. Global Candesartan by: Doses (Volume)
        • 5.3.2.1. 4 mg
        • 5.3.2.2. 8 mg
        • 5.3.2.3. 16 mg
        • 5.3.2.4. 32 mg
      • 5.3.3. Global Candesartan by: Distribution Channel (Volume)
        • 5.3.3.1. Hospital Pharmacies
        • 5.3.3.2. Retail Pharmacies
        • 5.3.3.3. Online Pharmacies
      • 5.3.4. Global Candesartan by: End User (Volume)
        • 5.3.4.1. Adult
        • 5.3.4.2. Children and Adolescent
      • 5.3.5. Global Candesartan Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Candesartan (Price)
  • 6. Candesartan: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Alvogen (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Ahn-Gook Pharmaceutical Co., Ltd. (South Korea)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. GlaxoSmithKline plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Tocris Bioscience (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abmole (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck KGaA (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AstraZeneca (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. ANI Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Shenzhen HEC Industrial Development Co., Ltd. (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Candesartan Sale, by Application, Doses, Distribution Channel, End User and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Candesartan (Value)
      • 7.2.1. Global Candesartan by: Application (Value)
        • 7.2.1.1. Hypertension
        • 7.2.1.2. Cardiovascular Risks
        • 7.2.1.3. Chronic Kidney Diseases
      • 7.2.2. Global Candesartan by: Doses (Value)
        • 7.2.2.1. 4 mg
        • 7.2.2.2. 8 mg
        • 7.2.2.3. 16 mg
        • 7.2.2.4. 32 mg
      • 7.2.3. Global Candesartan by: Distribution Channel (Value)
        • 7.2.3.1. Hospital Pharmacies
        • 7.2.3.2. Retail Pharmacies
        • 7.2.3.3. Online Pharmacies
      • 7.2.4. Global Candesartan by: End User (Value)
        • 7.2.4.1. Adult
        • 7.2.4.2. Children and Adolescent
      • 7.2.5. Global Candesartan Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Candesartan (Volume)
      • 7.3.1. Global Candesartan by: Application (Volume)
        • 7.3.1.1. Hypertension
        • 7.3.1.2. Cardiovascular Risks
        • 7.3.1.3. Chronic Kidney Diseases
      • 7.3.2. Global Candesartan by: Doses (Volume)
        • 7.3.2.1. 4 mg
        • 7.3.2.2. 8 mg
        • 7.3.2.3. 16 mg
        • 7.3.2.4. 32 mg
      • 7.3.3. Global Candesartan by: Distribution Channel (Volume)
        • 7.3.3.1. Hospital Pharmacies
        • 7.3.3.2. Retail Pharmacies
        • 7.3.3.3. Online Pharmacies
      • 7.3.4. Global Candesartan by: End User (Volume)
        • 7.3.4.1. Adult
        • 7.3.4.2. Children and Adolescent
      • 7.3.5. Global Candesartan Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Candesartan (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Candesartan: by Application(USD Million)
  • Table 2. Candesartan Hypertension , by Region USD Million (2017-2022)
  • Table 3. Candesartan Cardiovascular Risks , by Region USD Million (2017-2022)
  • Table 4. Candesartan Chronic Kidney Diseases , by Region USD Million (2017-2022)
  • Table 5. Candesartan: by Doses(USD Million)
  • Table 6. Candesartan 4 mg , by Region USD Million (2017-2022)
  • Table 7. Candesartan 8 mg , by Region USD Million (2017-2022)
  • Table 8. Candesartan 16 mg , by Region USD Million (2017-2022)
  • Table 9. Candesartan 32 mg , by Region USD Million (2017-2022)
  • Table 10. Candesartan: by Distribution Channel(USD Million)
  • Table 11. Candesartan Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 12. Candesartan Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 13. Candesartan Online Pharmacies , by Region USD Million (2017-2022)
  • Table 14. Candesartan: by End User(USD Million)
  • Table 15. Candesartan Adult , by Region USD Million (2017-2022)
  • Table 16. Candesartan Children and Adolescent , by Region USD Million (2017-2022)
  • Table 17. South America Candesartan, by Country USD Million (2017-2022)
  • Table 18. South America Candesartan, by Application USD Million (2017-2022)
  • Table 19. South America Candesartan, by Doses USD Million (2017-2022)
  • Table 20. South America Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 21. South America Candesartan, by End User USD Million (2017-2022)
  • Table 22. Brazil Candesartan, by Application USD Million (2017-2022)
  • Table 23. Brazil Candesartan, by Doses USD Million (2017-2022)
  • Table 24. Brazil Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 25. Brazil Candesartan, by End User USD Million (2017-2022)
  • Table 26. Argentina Candesartan, by Application USD Million (2017-2022)
  • Table 27. Argentina Candesartan, by Doses USD Million (2017-2022)
  • Table 28. Argentina Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 29. Argentina Candesartan, by End User USD Million (2017-2022)
  • Table 30. Rest of South America Candesartan, by Application USD Million (2017-2022)
  • Table 31. Rest of South America Candesartan, by Doses USD Million (2017-2022)
  • Table 32. Rest of South America Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 33. Rest of South America Candesartan, by End User USD Million (2017-2022)
  • Table 34. Asia Pacific Candesartan, by Country USD Million (2017-2022)
  • Table 35. Asia Pacific Candesartan, by Application USD Million (2017-2022)
  • Table 36. Asia Pacific Candesartan, by Doses USD Million (2017-2022)
  • Table 37. Asia Pacific Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 38. Asia Pacific Candesartan, by End User USD Million (2017-2022)
  • Table 39. China Candesartan, by Application USD Million (2017-2022)
  • Table 40. China Candesartan, by Doses USD Million (2017-2022)
  • Table 41. China Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 42. China Candesartan, by End User USD Million (2017-2022)
  • Table 43. Japan Candesartan, by Application USD Million (2017-2022)
  • Table 44. Japan Candesartan, by Doses USD Million (2017-2022)
  • Table 45. Japan Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 46. Japan Candesartan, by End User USD Million (2017-2022)
  • Table 47. India Candesartan, by Application USD Million (2017-2022)
  • Table 48. India Candesartan, by Doses USD Million (2017-2022)
  • Table 49. India Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 50. India Candesartan, by End User USD Million (2017-2022)
  • Table 51. South Korea Candesartan, by Application USD Million (2017-2022)
  • Table 52. South Korea Candesartan, by Doses USD Million (2017-2022)
  • Table 53. South Korea Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 54. South Korea Candesartan, by End User USD Million (2017-2022)
  • Table 55. Taiwan Candesartan, by Application USD Million (2017-2022)
  • Table 56. Taiwan Candesartan, by Doses USD Million (2017-2022)
  • Table 57. Taiwan Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 58. Taiwan Candesartan, by End User USD Million (2017-2022)
  • Table 59. Australia Candesartan, by Application USD Million (2017-2022)
  • Table 60. Australia Candesartan, by Doses USD Million (2017-2022)
  • Table 61. Australia Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 62. Australia Candesartan, by End User USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific Candesartan, by Application USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Candesartan, by Doses USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Candesartan, by End User USD Million (2017-2022)
  • Table 67. Europe Candesartan, by Country USD Million (2017-2022)
  • Table 68. Europe Candesartan, by Application USD Million (2017-2022)
  • Table 69. Europe Candesartan, by Doses USD Million (2017-2022)
  • Table 70. Europe Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 71. Europe Candesartan, by End User USD Million (2017-2022)
  • Table 72. Germany Candesartan, by Application USD Million (2017-2022)
  • Table 73. Germany Candesartan, by Doses USD Million (2017-2022)
  • Table 74. Germany Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 75. Germany Candesartan, by End User USD Million (2017-2022)
  • Table 76. France Candesartan, by Application USD Million (2017-2022)
  • Table 77. France Candesartan, by Doses USD Million (2017-2022)
  • Table 78. France Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 79. France Candesartan, by End User USD Million (2017-2022)
  • Table 80. Italy Candesartan, by Application USD Million (2017-2022)
  • Table 81. Italy Candesartan, by Doses USD Million (2017-2022)
  • Table 82. Italy Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 83. Italy Candesartan, by End User USD Million (2017-2022)
  • Table 84. United Kingdom Candesartan, by Application USD Million (2017-2022)
  • Table 85. United Kingdom Candesartan, by Doses USD Million (2017-2022)
  • Table 86. United Kingdom Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 87. United Kingdom Candesartan, by End User USD Million (2017-2022)
  • Table 88. Netherlands Candesartan, by Application USD Million (2017-2022)
  • Table 89. Netherlands Candesartan, by Doses USD Million (2017-2022)
  • Table 90. Netherlands Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 91. Netherlands Candesartan, by End User USD Million (2017-2022)
  • Table 92. Rest of Europe Candesartan, by Application USD Million (2017-2022)
  • Table 93. Rest of Europe Candesartan, by Doses USD Million (2017-2022)
  • Table 94. Rest of Europe Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 95. Rest of Europe Candesartan, by End User USD Million (2017-2022)
  • Table 96. MEA Candesartan, by Country USD Million (2017-2022)
  • Table 97. MEA Candesartan, by Application USD Million (2017-2022)
  • Table 98. MEA Candesartan, by Doses USD Million (2017-2022)
  • Table 99. MEA Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 100. MEA Candesartan, by End User USD Million (2017-2022)
  • Table 101. Middle East Candesartan, by Application USD Million (2017-2022)
  • Table 102. Middle East Candesartan, by Doses USD Million (2017-2022)
  • Table 103. Middle East Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 104. Middle East Candesartan, by End User USD Million (2017-2022)
  • Table 105. Africa Candesartan, by Application USD Million (2017-2022)
  • Table 106. Africa Candesartan, by Doses USD Million (2017-2022)
  • Table 107. Africa Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 108. Africa Candesartan, by End User USD Million (2017-2022)
  • Table 109. North America Candesartan, by Country USD Million (2017-2022)
  • Table 110. North America Candesartan, by Application USD Million (2017-2022)
  • Table 111. North America Candesartan, by Doses USD Million (2017-2022)
  • Table 112. North America Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 113. North America Candesartan, by End User USD Million (2017-2022)
  • Table 114. United States Candesartan, by Application USD Million (2017-2022)
  • Table 115. United States Candesartan, by Doses USD Million (2017-2022)
  • Table 116. United States Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 117. United States Candesartan, by End User USD Million (2017-2022)
  • Table 118. Canada Candesartan, by Application USD Million (2017-2022)
  • Table 119. Canada Candesartan, by Doses USD Million (2017-2022)
  • Table 120. Canada Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 121. Canada Candesartan, by End User USD Million (2017-2022)
  • Table 122. Mexico Candesartan, by Application USD Million (2017-2022)
  • Table 123. Mexico Candesartan, by Doses USD Million (2017-2022)
  • Table 124. Mexico Candesartan, by Distribution Channel USD Million (2017-2022)
  • Table 125. Mexico Candesartan, by End User USD Million (2017-2022)
  • Table 126. Candesartan Sales: by Application(Tonne)
  • Table 127. Candesartan Sales Hypertension , by Region Tonne (2017-2022)
  • Table 128. Candesartan Sales Cardiovascular Risks , by Region Tonne (2017-2022)
  • Table 129. Candesartan Sales Chronic Kidney Diseases , by Region Tonne (2017-2022)
  • Table 130. Candesartan Sales: by Doses(Tonne)
  • Table 131. Candesartan Sales 4 mg , by Region Tonne (2017-2022)
  • Table 132. Candesartan Sales 8 mg , by Region Tonne (2017-2022)
  • Table 133. Candesartan Sales 16 mg , by Region Tonne (2017-2022)
  • Table 134. Candesartan Sales 32 mg , by Region Tonne (2017-2022)
  • Table 135. Candesartan Sales: by Distribution Channel(Tonne)
  • Table 136. Candesartan Sales Hospital Pharmacies , by Region Tonne (2017-2022)
  • Table 137. Candesartan Sales Retail Pharmacies , by Region Tonne (2017-2022)
  • Table 138. Candesartan Sales Online Pharmacies , by Region Tonne (2017-2022)
  • Table 139. Candesartan Sales: by End User(Tonne)
  • Table 140. Candesartan Sales Adult , by Region Tonne (2017-2022)
  • Table 141. Candesartan Sales Children and Adolescent , by Region Tonne (2017-2022)
  • Table 142. South America Candesartan Sales, by Country Tonne (2017-2022)
  • Table 143. South America Candesartan Sales, by Application Tonne (2017-2022)
  • Table 144. South America Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 145. South America Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 146. South America Candesartan Sales, by End User Tonne (2017-2022)
  • Table 147. Brazil Candesartan Sales, by Application Tonne (2017-2022)
  • Table 148. Brazil Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 149. Brazil Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 150. Brazil Candesartan Sales, by End User Tonne (2017-2022)
  • Table 151. Argentina Candesartan Sales, by Application Tonne (2017-2022)
  • Table 152. Argentina Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 153. Argentina Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 154. Argentina Candesartan Sales, by End User Tonne (2017-2022)
  • Table 155. Rest of South America Candesartan Sales, by Application Tonne (2017-2022)
  • Table 156. Rest of South America Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 157. Rest of South America Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 158. Rest of South America Candesartan Sales, by End User Tonne (2017-2022)
  • Table 159. Asia Pacific Candesartan Sales, by Country Tonne (2017-2022)
  • Table 160. Asia Pacific Candesartan Sales, by Application Tonne (2017-2022)
  • Table 161. Asia Pacific Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 162. Asia Pacific Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 163. Asia Pacific Candesartan Sales, by End User Tonne (2017-2022)
  • Table 164. China Candesartan Sales, by Application Tonne (2017-2022)
  • Table 165. China Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 166. China Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 167. China Candesartan Sales, by End User Tonne (2017-2022)
  • Table 168. Japan Candesartan Sales, by Application Tonne (2017-2022)
  • Table 169. Japan Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 170. Japan Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 171. Japan Candesartan Sales, by End User Tonne (2017-2022)
  • Table 172. India Candesartan Sales, by Application Tonne (2017-2022)
  • Table 173. India Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 174. India Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 175. India Candesartan Sales, by End User Tonne (2017-2022)
  • Table 176. South Korea Candesartan Sales, by Application Tonne (2017-2022)
  • Table 177. South Korea Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 178. South Korea Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 179. South Korea Candesartan Sales, by End User Tonne (2017-2022)
  • Table 180. Taiwan Candesartan Sales, by Application Tonne (2017-2022)
  • Table 181. Taiwan Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 182. Taiwan Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 183. Taiwan Candesartan Sales, by End User Tonne (2017-2022)
  • Table 184. Australia Candesartan Sales, by Application Tonne (2017-2022)
  • Table 185. Australia Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 186. Australia Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 187. Australia Candesartan Sales, by End User Tonne (2017-2022)
  • Table 188. Rest of Asia-Pacific Candesartan Sales, by Application Tonne (2017-2022)
  • Table 189. Rest of Asia-Pacific Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 190. Rest of Asia-Pacific Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 191. Rest of Asia-Pacific Candesartan Sales, by End User Tonne (2017-2022)
  • Table 192. Europe Candesartan Sales, by Country Tonne (2017-2022)
  • Table 193. Europe Candesartan Sales, by Application Tonne (2017-2022)
  • Table 194. Europe Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 195. Europe Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 196. Europe Candesartan Sales, by End User Tonne (2017-2022)
  • Table 197. Germany Candesartan Sales, by Application Tonne (2017-2022)
  • Table 198. Germany Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 199. Germany Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 200. Germany Candesartan Sales, by End User Tonne (2017-2022)
  • Table 201. France Candesartan Sales, by Application Tonne (2017-2022)
  • Table 202. France Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 203. France Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 204. France Candesartan Sales, by End User Tonne (2017-2022)
  • Table 205. Italy Candesartan Sales, by Application Tonne (2017-2022)
  • Table 206. Italy Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 207. Italy Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 208. Italy Candesartan Sales, by End User Tonne (2017-2022)
  • Table 209. United Kingdom Candesartan Sales, by Application Tonne (2017-2022)
  • Table 210. United Kingdom Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 211. United Kingdom Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 212. United Kingdom Candesartan Sales, by End User Tonne (2017-2022)
  • Table 213. Netherlands Candesartan Sales, by Application Tonne (2017-2022)
  • Table 214. Netherlands Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 215. Netherlands Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 216. Netherlands Candesartan Sales, by End User Tonne (2017-2022)
  • Table 217. Rest of Europe Candesartan Sales, by Application Tonne (2017-2022)
  • Table 218. Rest of Europe Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 219. Rest of Europe Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 220. Rest of Europe Candesartan Sales, by End User Tonne (2017-2022)
  • Table 221. MEA Candesartan Sales, by Country Tonne (2017-2022)
  • Table 222. MEA Candesartan Sales, by Application Tonne (2017-2022)
  • Table 223. MEA Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 224. MEA Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 225. MEA Candesartan Sales, by End User Tonne (2017-2022)
  • Table 226. Middle East Candesartan Sales, by Application Tonne (2017-2022)
  • Table 227. Middle East Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 228. Middle East Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 229. Middle East Candesartan Sales, by End User Tonne (2017-2022)
  • Table 230. Africa Candesartan Sales, by Application Tonne (2017-2022)
  • Table 231. Africa Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 232. Africa Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 233. Africa Candesartan Sales, by End User Tonne (2017-2022)
  • Table 234. North America Candesartan Sales, by Country Tonne (2017-2022)
  • Table 235. North America Candesartan Sales, by Application Tonne (2017-2022)
  • Table 236. North America Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 237. North America Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 238. North America Candesartan Sales, by End User Tonne (2017-2022)
  • Table 239. United States Candesartan Sales, by Application Tonne (2017-2022)
  • Table 240. United States Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 241. United States Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 242. United States Candesartan Sales, by End User Tonne (2017-2022)
  • Table 243. Canada Candesartan Sales, by Application Tonne (2017-2022)
  • Table 244. Canada Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 245. Canada Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 246. Canada Candesartan Sales, by End User Tonne (2017-2022)
  • Table 247. Mexico Candesartan Sales, by Application Tonne (2017-2022)
  • Table 248. Mexico Candesartan Sales, by Doses Tonne (2017-2022)
  • Table 249. Mexico Candesartan Sales, by Distribution Channel Tonne (2017-2022)
  • Table 250. Mexico Candesartan Sales, by End User Tonne (2017-2022)
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Candesartan: by Application(USD Million)
  • Table 262. Candesartan Hypertension , by Region USD Million (2023-2028)
  • Table 263. Candesartan Cardiovascular Risks , by Region USD Million (2023-2028)
  • Table 264. Candesartan Chronic Kidney Diseases , by Region USD Million (2023-2028)
  • Table 265. Candesartan: by Doses(USD Million)
  • Table 266. Candesartan 4 mg , by Region USD Million (2023-2028)
  • Table 267. Candesartan 8 mg , by Region USD Million (2023-2028)
  • Table 268. Candesartan 16 mg , by Region USD Million (2023-2028)
  • Table 269. Candesartan 32 mg , by Region USD Million (2023-2028)
  • Table 270. Candesartan: by Distribution Channel(USD Million)
  • Table 271. Candesartan Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 272. Candesartan Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 273. Candesartan Online Pharmacies , by Region USD Million (2023-2028)
  • Table 274. Candesartan: by End User(USD Million)
  • Table 275. Candesartan Adult , by Region USD Million (2023-2028)
  • Table 276. Candesartan Children and Adolescent , by Region USD Million (2023-2028)
  • Table 277. South America Candesartan, by Country USD Million (2023-2028)
  • Table 278. South America Candesartan, by Application USD Million (2023-2028)
  • Table 279. South America Candesartan, by Doses USD Million (2023-2028)
  • Table 280. South America Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 281. South America Candesartan, by End User USD Million (2023-2028)
  • Table 282. Brazil Candesartan, by Application USD Million (2023-2028)
  • Table 283. Brazil Candesartan, by Doses USD Million (2023-2028)
  • Table 284. Brazil Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 285. Brazil Candesartan, by End User USD Million (2023-2028)
  • Table 286. Argentina Candesartan, by Application USD Million (2023-2028)
  • Table 287. Argentina Candesartan, by Doses USD Million (2023-2028)
  • Table 288. Argentina Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 289. Argentina Candesartan, by End User USD Million (2023-2028)
  • Table 290. Rest of South America Candesartan, by Application USD Million (2023-2028)
  • Table 291. Rest of South America Candesartan, by Doses USD Million (2023-2028)
  • Table 292. Rest of South America Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 293. Rest of South America Candesartan, by End User USD Million (2023-2028)
  • Table 294. Asia Pacific Candesartan, by Country USD Million (2023-2028)
  • Table 295. Asia Pacific Candesartan, by Application USD Million (2023-2028)
  • Table 296. Asia Pacific Candesartan, by Doses USD Million (2023-2028)
  • Table 297. Asia Pacific Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 298. Asia Pacific Candesartan, by End User USD Million (2023-2028)
  • Table 299. China Candesartan, by Application USD Million (2023-2028)
  • Table 300. China Candesartan, by Doses USD Million (2023-2028)
  • Table 301. China Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 302. China Candesartan, by End User USD Million (2023-2028)
  • Table 303. Japan Candesartan, by Application USD Million (2023-2028)
  • Table 304. Japan Candesartan, by Doses USD Million (2023-2028)
  • Table 305. Japan Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 306. Japan Candesartan, by End User USD Million (2023-2028)
  • Table 307. India Candesartan, by Application USD Million (2023-2028)
  • Table 308. India Candesartan, by Doses USD Million (2023-2028)
  • Table 309. India Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 310. India Candesartan, by End User USD Million (2023-2028)
  • Table 311. South Korea Candesartan, by Application USD Million (2023-2028)
  • Table 312. South Korea Candesartan, by Doses USD Million (2023-2028)
  • Table 313. South Korea Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 314. South Korea Candesartan, by End User USD Million (2023-2028)
  • Table 315. Taiwan Candesartan, by Application USD Million (2023-2028)
  • Table 316. Taiwan Candesartan, by Doses USD Million (2023-2028)
  • Table 317. Taiwan Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 318. Taiwan Candesartan, by End User USD Million (2023-2028)
  • Table 319. Australia Candesartan, by Application USD Million (2023-2028)
  • Table 320. Australia Candesartan, by Doses USD Million (2023-2028)
  • Table 321. Australia Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 322. Australia Candesartan, by End User USD Million (2023-2028)
  • Table 323. Rest of Asia-Pacific Candesartan, by Application USD Million (2023-2028)
  • Table 324. Rest of Asia-Pacific Candesartan, by Doses USD Million (2023-2028)
  • Table 325. Rest of Asia-Pacific Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 326. Rest of Asia-Pacific Candesartan, by End User USD Million (2023-2028)
  • Table 327. Europe Candesartan, by Country USD Million (2023-2028)
  • Table 328. Europe Candesartan, by Application USD Million (2023-2028)
  • Table 329. Europe Candesartan, by Doses USD Million (2023-2028)
  • Table 330. Europe Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 331. Europe Candesartan, by End User USD Million (2023-2028)
  • Table 332. Germany Candesartan, by Application USD Million (2023-2028)
  • Table 333. Germany Candesartan, by Doses USD Million (2023-2028)
  • Table 334. Germany Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 335. Germany Candesartan, by End User USD Million (2023-2028)
  • Table 336. France Candesartan, by Application USD Million (2023-2028)
  • Table 337. France Candesartan, by Doses USD Million (2023-2028)
  • Table 338. France Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 339. France Candesartan, by End User USD Million (2023-2028)
  • Table 340. Italy Candesartan, by Application USD Million (2023-2028)
  • Table 341. Italy Candesartan, by Doses USD Million (2023-2028)
  • Table 342. Italy Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 343. Italy Candesartan, by End User USD Million (2023-2028)
  • Table 344. United Kingdom Candesartan, by Application USD Million (2023-2028)
  • Table 345. United Kingdom Candesartan, by Doses USD Million (2023-2028)
  • Table 346. United Kingdom Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 347. United Kingdom Candesartan, by End User USD Million (2023-2028)
  • Table 348. Netherlands Candesartan, by Application USD Million (2023-2028)
  • Table 349. Netherlands Candesartan, by Doses USD Million (2023-2028)
  • Table 350. Netherlands Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 351. Netherlands Candesartan, by End User USD Million (2023-2028)
  • Table 352. Rest of Europe Candesartan, by Application USD Million (2023-2028)
  • Table 353. Rest of Europe Candesartan, by Doses USD Million (2023-2028)
  • Table 354. Rest of Europe Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 355. Rest of Europe Candesartan, by End User USD Million (2023-2028)
  • Table 356. MEA Candesartan, by Country USD Million (2023-2028)
  • Table 357. MEA Candesartan, by Application USD Million (2023-2028)
  • Table 358. MEA Candesartan, by Doses USD Million (2023-2028)
  • Table 359. MEA Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 360. MEA Candesartan, by End User USD Million (2023-2028)
  • Table 361. Middle East Candesartan, by Application USD Million (2023-2028)
  • Table 362. Middle East Candesartan, by Doses USD Million (2023-2028)
  • Table 363. Middle East Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 364. Middle East Candesartan, by End User USD Million (2023-2028)
  • Table 365. Africa Candesartan, by Application USD Million (2023-2028)
  • Table 366. Africa Candesartan, by Doses USD Million (2023-2028)
  • Table 367. Africa Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 368. Africa Candesartan, by End User USD Million (2023-2028)
  • Table 369. North America Candesartan, by Country USD Million (2023-2028)
  • Table 370. North America Candesartan, by Application USD Million (2023-2028)
  • Table 371. North America Candesartan, by Doses USD Million (2023-2028)
  • Table 372. North America Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 373. North America Candesartan, by End User USD Million (2023-2028)
  • Table 374. United States Candesartan, by Application USD Million (2023-2028)
  • Table 375. United States Candesartan, by Doses USD Million (2023-2028)
  • Table 376. United States Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 377. United States Candesartan, by End User USD Million (2023-2028)
  • Table 378. Canada Candesartan, by Application USD Million (2023-2028)
  • Table 379. Canada Candesartan, by Doses USD Million (2023-2028)
  • Table 380. Canada Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 381. Canada Candesartan, by End User USD Million (2023-2028)
  • Table 382. Mexico Candesartan, by Application USD Million (2023-2028)
  • Table 383. Mexico Candesartan, by Doses USD Million (2023-2028)
  • Table 384. Mexico Candesartan, by Distribution Channel USD Million (2023-2028)
  • Table 385. Mexico Candesartan, by End User USD Million (2023-2028)
  • Table 386. Candesartan Sales: by Application(Tonne)
  • Table 387. Candesartan Sales Hypertension , by Region Tonne (2023-2028)
  • Table 388. Candesartan Sales Cardiovascular Risks , by Region Tonne (2023-2028)
  • Table 389. Candesartan Sales Chronic Kidney Diseases , by Region Tonne (2023-2028)
  • Table 390. Candesartan Sales: by Doses(Tonne)
  • Table 391. Candesartan Sales 4 mg , by Region Tonne (2023-2028)
  • Table 392. Candesartan Sales 8 mg , by Region Tonne (2023-2028)
  • Table 393. Candesartan Sales 16 mg , by Region Tonne (2023-2028)
  • Table 394. Candesartan Sales 32 mg , by Region Tonne (2023-2028)
  • Table 395. Candesartan Sales: by Distribution Channel(Tonne)
  • Table 396. Candesartan Sales Hospital Pharmacies , by Region Tonne (2023-2028)
  • Table 397. Candesartan Sales Retail Pharmacies , by Region Tonne (2023-2028)
  • Table 398. Candesartan Sales Online Pharmacies , by Region Tonne (2023-2028)
  • Table 399. Candesartan Sales: by End User(Tonne)
  • Table 400. Candesartan Sales Adult , by Region Tonne (2023-2028)
  • Table 401. Candesartan Sales Children and Adolescent , by Region Tonne (2023-2028)
  • Table 402. South America Candesartan Sales, by Country Tonne (2023-2028)
  • Table 403. South America Candesartan Sales, by Application Tonne (2023-2028)
  • Table 404. South America Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 405. South America Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 406. South America Candesartan Sales, by End User Tonne (2023-2028)
  • Table 407. Brazil Candesartan Sales, by Application Tonne (2023-2028)
  • Table 408. Brazil Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 409. Brazil Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 410. Brazil Candesartan Sales, by End User Tonne (2023-2028)
  • Table 411. Argentina Candesartan Sales, by Application Tonne (2023-2028)
  • Table 412. Argentina Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 413. Argentina Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 414. Argentina Candesartan Sales, by End User Tonne (2023-2028)
  • Table 415. Rest of South America Candesartan Sales, by Application Tonne (2023-2028)
  • Table 416. Rest of South America Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 417. Rest of South America Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 418. Rest of South America Candesartan Sales, by End User Tonne (2023-2028)
  • Table 419. Asia Pacific Candesartan Sales, by Country Tonne (2023-2028)
  • Table 420. Asia Pacific Candesartan Sales, by Application Tonne (2023-2028)
  • Table 421. Asia Pacific Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 422. Asia Pacific Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 423. Asia Pacific Candesartan Sales, by End User Tonne (2023-2028)
  • Table 424. China Candesartan Sales, by Application Tonne (2023-2028)
  • Table 425. China Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 426. China Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 427. China Candesartan Sales, by End User Tonne (2023-2028)
  • Table 428. Japan Candesartan Sales, by Application Tonne (2023-2028)
  • Table 429. Japan Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 430. Japan Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 431. Japan Candesartan Sales, by End User Tonne (2023-2028)
  • Table 432. India Candesartan Sales, by Application Tonne (2023-2028)
  • Table 433. India Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 434. India Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 435. India Candesartan Sales, by End User Tonne (2023-2028)
  • Table 436. South Korea Candesartan Sales, by Application Tonne (2023-2028)
  • Table 437. South Korea Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 438. South Korea Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 439. South Korea Candesartan Sales, by End User Tonne (2023-2028)
  • Table 440. Taiwan Candesartan Sales, by Application Tonne (2023-2028)
  • Table 441. Taiwan Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 442. Taiwan Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 443. Taiwan Candesartan Sales, by End User Tonne (2023-2028)
  • Table 444. Australia Candesartan Sales, by Application Tonne (2023-2028)
  • Table 445. Australia Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 446. Australia Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 447. Australia Candesartan Sales, by End User Tonne (2023-2028)
  • Table 448. Rest of Asia-Pacific Candesartan Sales, by Application Tonne (2023-2028)
  • Table 449. Rest of Asia-Pacific Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 450. Rest of Asia-Pacific Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 451. Rest of Asia-Pacific Candesartan Sales, by End User Tonne (2023-2028)
  • Table 452. Europe Candesartan Sales, by Country Tonne (2023-2028)
  • Table 453. Europe Candesartan Sales, by Application Tonne (2023-2028)
  • Table 454. Europe Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 455. Europe Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 456. Europe Candesartan Sales, by End User Tonne (2023-2028)
  • Table 457. Germany Candesartan Sales, by Application Tonne (2023-2028)
  • Table 458. Germany Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 459. Germany Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 460. Germany Candesartan Sales, by End User Tonne (2023-2028)
  • Table 461. France Candesartan Sales, by Application Tonne (2023-2028)
  • Table 462. France Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 463. France Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 464. France Candesartan Sales, by End User Tonne (2023-2028)
  • Table 465. Italy Candesartan Sales, by Application Tonne (2023-2028)
  • Table 466. Italy Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 467. Italy Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 468. Italy Candesartan Sales, by End User Tonne (2023-2028)
  • Table 469. United Kingdom Candesartan Sales, by Application Tonne (2023-2028)
  • Table 470. United Kingdom Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 471. United Kingdom Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 472. United Kingdom Candesartan Sales, by End User Tonne (2023-2028)
  • Table 473. Netherlands Candesartan Sales, by Application Tonne (2023-2028)
  • Table 474. Netherlands Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 475. Netherlands Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 476. Netherlands Candesartan Sales, by End User Tonne (2023-2028)
  • Table 477. Rest of Europe Candesartan Sales, by Application Tonne (2023-2028)
  • Table 478. Rest of Europe Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 479. Rest of Europe Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 480. Rest of Europe Candesartan Sales, by End User Tonne (2023-2028)
  • Table 481. MEA Candesartan Sales, by Country Tonne (2023-2028)
  • Table 482. MEA Candesartan Sales, by Application Tonne (2023-2028)
  • Table 483. MEA Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 484. MEA Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 485. MEA Candesartan Sales, by End User Tonne (2023-2028)
  • Table 486. Middle East Candesartan Sales, by Application Tonne (2023-2028)
  • Table 487. Middle East Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 488. Middle East Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 489. Middle East Candesartan Sales, by End User Tonne (2023-2028)
  • Table 490. Africa Candesartan Sales, by Application Tonne (2023-2028)
  • Table 491. Africa Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 492. Africa Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 493. Africa Candesartan Sales, by End User Tonne (2023-2028)
  • Table 494. North America Candesartan Sales, by Country Tonne (2023-2028)
  • Table 495. North America Candesartan Sales, by Application Tonne (2023-2028)
  • Table 496. North America Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 497. North America Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 498. North America Candesartan Sales, by End User Tonne (2023-2028)
  • Table 499. United States Candesartan Sales, by Application Tonne (2023-2028)
  • Table 500. United States Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 501. United States Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 502. United States Candesartan Sales, by End User Tonne (2023-2028)
  • Table 503. Canada Candesartan Sales, by Application Tonne (2023-2028)
  • Table 504. Canada Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 505. Canada Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 506. Canada Candesartan Sales, by End User Tonne (2023-2028)
  • Table 507. Mexico Candesartan Sales, by Application Tonne (2023-2028)
  • Table 508. Mexico Candesartan Sales, by Doses Tonne (2023-2028)
  • Table 509. Mexico Candesartan Sales, by Distribution Channel Tonne (2023-2028)
  • Table 510. Mexico Candesartan Sales, by End User Tonne (2023-2028)
  • Table 511. Research Programs/Design for This Report
  • Table 512. Key Data Information from Secondary Sources
  • Table 513. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Candesartan: by Application USD Million (2017-2022)
  • Figure 5. Global Candesartan: by Doses USD Million (2017-2022)
  • Figure 6. Global Candesartan: by Distribution Channel USD Million (2017-2022)
  • Figure 7. Global Candesartan: by End User USD Million (2017-2022)
  • Figure 8. South America Candesartan Share (%), by Country
  • Figure 9. Asia Pacific Candesartan Share (%), by Country
  • Figure 10. Europe Candesartan Share (%), by Country
  • Figure 11. MEA Candesartan Share (%), by Country
  • Figure 12. North America Candesartan Share (%), by Country
  • Figure 13. Global Candesartan: by Application Tonne (2017-2022)
  • Figure 14. Global Candesartan: by Doses Tonne (2017-2022)
  • Figure 15. Global Candesartan: by Distribution Channel Tonne (2017-2022)
  • Figure 16. Global Candesartan: by End User Tonne (2017-2022)
  • Figure 17. South America Candesartan Share (%), by Country
  • Figure 18. Asia Pacific Candesartan Share (%), by Country
  • Figure 19. Europe Candesartan Share (%), by Country
  • Figure 20. MEA Candesartan Share (%), by Country
  • Figure 21. North America Candesartan Share (%), by Country
  • Figure 22. Global Candesartan share by Players 2022 (%)
  • Figure 23. Global Candesartan share by Players (Top 3) 2022(%)
  • Figure 24. Global Candesartan share by Players (Top 5) 2022(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Bayer AG (Germany) Revenue: by Geography 2022
  • Figure 28. Alvogen (United States) Revenue, Net Income and Gross profit
  • Figure 29. Alvogen (United States) Revenue: by Geography 2022
  • Figure 30. Ahn-Gook Pharmaceutical Co., Ltd. (South Korea) Revenue, Net Income and Gross profit
  • Figure 31. Ahn-Gook Pharmaceutical Co., Ltd. (South Korea) Revenue: by Geography 2022
  • Figure 32. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 34. Tocris Bioscience (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. Tocris Bioscience (United Kingdom) Revenue: by Geography 2022
  • Figure 36. Abmole (United States) Revenue, Net Income and Gross profit
  • Figure 37. Abmole (United States) Revenue: by Geography 2022
  • Figure 38. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 39. Merck KGaA (Germany) Revenue: by Geography 2022
  • Figure 40. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 41. AstraZeneca (United Kingdom) Revenue: by Geography 2022
  • Figure 42. ANI Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 43. ANI Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 44. Shenzhen HEC Industrial Development Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 45. Shenzhen HEC Industrial Development Co., Ltd. (China) Revenue: by Geography 2022
  • Figure 46. Global Candesartan: by Application USD Million (2023-2028)
  • Figure 47. Global Candesartan: by Doses USD Million (2023-2028)
  • Figure 48. Global Candesartan: by Distribution Channel USD Million (2023-2028)
  • Figure 49. Global Candesartan: by End User USD Million (2023-2028)
  • Figure 50. South America Candesartan Share (%), by Country
  • Figure 51. Asia Pacific Candesartan Share (%), by Country
  • Figure 52. Europe Candesartan Share (%), by Country
  • Figure 53. MEA Candesartan Share (%), by Country
  • Figure 54. North America Candesartan Share (%), by Country
  • Figure 55. Global Candesartan: by Application Tonne (2023-2028)
  • Figure 56. Global Candesartan: by Doses Tonne (2023-2028)
  • Figure 57. Global Candesartan: by Distribution Channel Tonne (2023-2028)
  • Figure 58. Global Candesartan: by End User Tonne (2023-2028)
  • Figure 59. South America Candesartan Share (%), by Country
  • Figure 60. Asia Pacific Candesartan Share (%), by Country
  • Figure 61. Europe Candesartan Share (%), by Country
  • Figure 62. MEA Candesartan Share (%), by Country
  • Figure 63. North America Candesartan Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bayer AG (Germany)
  • Alvogen (United States)
  • Ahn-Gook Pharmaceutical Co., Ltd. (South Korea)
  • GlaxoSmithKline plc (United Kingdom)
  • Tocris Bioscience (United Kingdom)
  • Abmole (United States)
  • Merck KGaA (Germany)
  • AstraZeneca (United Kingdom)
  • ANI Pharmaceuticals (United States)
  • Shenzhen HEC Industrial Development Co., Ltd. (China)
Additional players considered in the study are as follows:
Mylan N.V. (United States) , Cadila Healthcare (India)
Select User Access Type

Key Highlights of Report


May 2023 245 Pages 65 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Candesartan Quantitative research analysis
Global Candesartan Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Candesartan market are Bayer AG (Germany), Alvogen (United States), Ahn-Gook Pharmaceutical Co., Ltd. (South Korea), GlaxoSmithKline plc (United Kingdom), Tocris Bioscience (United Kingdom), Abmole (United States), Merck KGaA (Germany), AstraZeneca (United Kingdom), ANI Pharmaceuticals (United States) and Shenzhen HEC Industrial Development Co., Ltd. (China), to name a few.
"Increasing Demand at Asia-Pacific Regions" is seen as one of major influencing trends for Candesartan Market during projected period 2022-2028.

Know More About Global Candesartan Report?

Have a Query? Click Here

Other Related Reports

Antifibrinolytic Drugs Comprehensive Study by Drug Type (Amicar, Aminocaproic acid, Aprotinin, Cyklokapron, Fibrinogen, human, Lysteda, RiaSTAP, Tranexamic acid injection, Tranexamic acid oral, Trasy...
$ 3750
Botulism Illness Comprehensive Study by Type (Antibiotics, Antitoxins, Other), Application (Hospitals, Clinics, Other), Distribution Channel (OTC, Prescribed) Players and Region - Global Market Outlo...
$ 3500
Drug Eluting Beads Comprehensive Study by Type (LC Beads, QuadraSpheres, Oncozene Beads), Application (Hospitals, Specialized Clinics, Ambulatory Surgical Centers, Research Centers), Drug (Doxorubici...
$ 3800
Breast Cancer Monoclonal Antibodies Comprehensive Study by Type (Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies), Application (Hospitals, Retail Pharm...
$ 3500
Sotalol Drug Comprehensive Study by Application (Ventricular Arrhythmias, Atrial Fibrillation/Flutter, Supraventricular Arrhythmias), Distribution Channel (Sales Channel Hospital Pharmacies, Drug Sto...
$ 3650
Eye Infections Treatment Comprehensive Study by Type (Gels and Creams, Eye Drops, Drug), Application (Ophthalmology Clinics, Hospitals, Others), Eye Infection (Conjunctivitis or Pink Eye, Viral Kerat...
$ 3750